<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id><journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098595</article-id><article-id pub-id-type="doi">10.3389/fneur.2025.1521112</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject><subj-group><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title>The effects of Leventhal&#x02019;s self-regulation model-based educational intervention on stress, anxiety, and depression in women with multiple sclerosis: a randomized educational trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Mahsa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2834513/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shamsikhani</surname><given-names>Soheila</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2856076/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Jadidi</surname><given-names>Ali</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1595209/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Rafiei</surname><given-names>Fatemeh</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Shazand School of Nursing, Arak University of Medical Sciences</institution>, <addr-line>Arak</addr-line>, <country>Iran</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Nursing, School of Nursing and Midwifery, Arak University of Medical Sciences</institution>, <addr-line>Arak</addr-line>, <country>Iran</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Emanuele D&#x02019;amico, University of Foggia, Italy</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Aurora Zangh&#x000ec;, Sant&#x02019;Elia Hospital, Italy</p><p>Xiaoyun Zhang, Shenzhen Longhua District Central Hospital, China</p></fn><corresp id="c001">*Correspondence: Soheila Shamsikhani, <email>Shamsikhani@arakmu.ac.ir</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1521112</elocation-id><history><date date-type="received"><day>01</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Hosseini, Shamsikhani, Jadidi and Rafiei.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Hosseini, Shamsikhani, Jadidi and Rafiei</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Background</title><p>Multiple sclerosis (MS) is a long-term, progressive neurological condition that affects the myelin sheath of nerve cells in the central nervous system. Mental health concerns are often overlooked in individuals with MS, stemming from various aspects of the illness, such as its inherent characteristics and symptoms. The present research aimed to examine the impact of Leventhal self-regulation training on stress, anxiety, and depression in MS patients.</p></sec><sec id="sec2"><title>Methods</title><p>The current study was conducted as a randomized educational trial of 60 women referred to the MS Association in Arak City in 2024. The study implemented self-regulation training via the Leventhal model, which consisted of an initial face-to-face session to provide basic knowledge, eight offline sessions, and two online group sessions. The data were input into SPSS 26 software. Chi-square tests and Fisher&#x02019;s exact tests were utilized, independent t-tests, and Mann&#x02013;Whitney&#x02019;s nonparametric equivalent. A repeated measures analysis of variance was conducted to assess the changes over three time points. Additionally, the Bonferroni <italic>post hoc</italic> correction was utilized. In the present study, data collection consisted of two parts: the demographic information form and the Depression Anxiety Stress Scale (DASS) questionnaire. The Iranian registry Clinical Trial code (IRCT) is IRCT20220703055351N3.</p></sec><sec id="sec3"><title>Result</title><p>The findings of this research indicated that there were no disparities in anxiety (<italic>p</italic>&#x0202f;=&#x0202f;0.072), stress (<italic>p</italic>&#x0202f;=&#x0202f;0.067), or depression (<italic>p</italic>&#x0202f;=&#x0202f;0.170) between the control and experimental groups before the intervention. The mean (&#x000b1; standard deviation) anxiety, stress, and depression scores of the experimental group changed from 4.89 (4.34), 8.55 (5.57), and 6.82 (4.26) to 1.96 (2.48), 4.93 (4.55), and 4.37 (3.73) after the intervention, respectively (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05).</p></sec><sec id="sec4"><title>Discussion</title><p>Recent research has shown that training based on the Leventhal model is effective in reducing stress, anxiety, and depression in MS patients. Additionally, the results showed that the ability of Leventhal training to improve depression was stable for one month.</p></sec><sec id="sec400"><title>Clinical trial registration</title><p><uri xlink:href="https://irct.behdasht.gov.ir/">https://irct.behdasht.gov.ir/</uri>, IRCT20220703055351N3.</p></sec></abstract><kwd-group><kwd>multiple sclerosis</kwd><kwd>Leventhal&#x02019;s self-regulation</kwd><kwd>anxiety</kwd><kwd>stress</kwd><kwd>depression</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. Arak University of Medical Sciences provided support for this research, which was undertaken by the first author as a component of her master&#x02019;s thesis. The funding source has no role in any stage of conducting this research.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="4"/><equation-count count="1"/><ref-count count="68"/><page-count count="10"/><word-count count="7127"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Multiple Sclerosis and Neuroimmunology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><label>1</label><title>Introduction</title><p>Multiple sclerosis (MS) is a chronic, degenerative neurological condition characterized by damage to the myelin sheath within the central nervous system (<xref rid="ref1" ref-type="bibr">1</xref>). In 2020, the global incidence of MS was reported at 35.9 cases per 100,000 individuals (<xref rid="ref2" ref-type="bibr">2</xref>). In Iran, approximately 100 out of every 100,000 people are diagnosed with MS, a figure that continues to rise (<xref rid="ref3" ref-type="bibr">3</xref>). Notably, around 75% of MS patients are female (<xref rid="ref4" ref-type="bibr">4</xref>), resulting in a higher prevalence of the disease among women in Iran compared to global averages (<xref rid="ref5" ref-type="bibr">5</xref>).</p><p>A significant concern in the management of MS is the often-overlooked mental health of those affected by the condition. The impact of MS on mental health is complex and multifaceted, typically arising from the disease&#x02019;s characteristics and its associated symptoms (<xref rid="ref6" ref-type="bibr">6</xref>). Psychological symptoms are frequently observed in individuals with MS; however, these symptoms often receive insufficient evaluation (<xref rid="ref7" ref-type="bibr">7</xref>). Additionally, cognitive impairments are common among MS patients (<xref rid="ref8" ref-type="bibr">8</xref>). Mental disorders, excluding schizophrenia, are more prevalent in MS patients than in the general population (<xref rid="ref9" ref-type="bibr">9</xref>). The occurrence of mental disorders, such as anxiety and depression, is notably high among MS patients, and these conditions are critical to consider due to their influence on treatment adherence and overall quality of life (<xref rid="ref10" ref-type="bibr">10</xref>). In fact, many individuals with MS experience the adverse effects of the disease, including anxiety, stress, and depression (<xref rid="ref11" ref-type="bibr">11</xref>). Research indicates that comorbidities, such as depression, anxiety, cerebrovascular and cardiovascular diseases, and autoimmune disorders like diabetes, are associated with MS. These comorbid conditions can exacerbate MS symptoms, affect treatment adherence, and influence therapeutic outcomes (<xref rid="ref12" ref-type="bibr">12</xref>). Consequently, anxiety, stress, and depression are regarded as both repercussions of MS and comorbidities.</p><p>The prevalence of anxiety and depression among MS patients is reported at 35.19 and 27.01%, respectively (<xref rid="ref13" ref-type="bibr">13</xref>). The overall prevalence of these mental health issues among Iranian individuals with MS is 47% (<xref rid="ref14" ref-type="bibr">14</xref>). Moreover, individuals with MS often experience heightened stress levels, which are believed to contribute to disease progression (<xref rid="ref15" ref-type="bibr">15</xref>). In patients with autoimmune diseases such as MS, increased production of proinflammatory cytokines is linked to depression (<xref rid="ref16" ref-type="bibr">16</xref>). Depression is a significant determinant of quality of life in MS patients and can even lead to suicidal ideation (<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>). Furthermore, anxiety and depression, as emotional responses, can influence adaptation to the disease and affect patients&#x02019; functional capabilities (<xref rid="ref19" ref-type="bibr">19</xref>). Therefore, prioritizing mental health aspects such as stress, anxiety, and depression in MS patients is essential.</p><p>In summary, MS can lead to various psychological consequences, including anxiety, stress, and depression, which can adversely affect multiple facets of health and overall well-being. One effective strategy for managing the physical and psychological complications associated with chronic diseases, including MS, is to enhance awareness and understanding of the disease.</p><p>A diminished perception of diseases is associated with an increase in negative outcomes, including stress, anxiety, and depression (<xref rid="ref20" ref-type="bibr">20</xref>). Numerous research initiatives have been undertaken to enhance the understanding of various diseases, leading to improved management of their associated complications. These initiatives encompass peer support groups (<xref rid="ref21" ref-type="bibr">21</xref>), religious psychotherapy methods (<xref rid="ref22" ref-type="bibr">22</xref>), psychological training for caregivers (<xref rid="ref23" ref-type="bibr">23</xref>), mindfulness-based cognitive therapy (<xref rid="ref24" ref-type="bibr">24</xref>), pet therapy (<xref rid="ref25" ref-type="bibr">25</xref>), and other interventions. However, these methods primarily focus on the cognitive dimension of illness perception. In contrast, Leventhal&#x02019;s self-regulation theory emphasizes the importance of both cognitive and emotional factors in enhancing illness perception.</p><p>Introduced by Leventhal et al. in 1980, the self-regulation model illustrates the connection between individuals&#x02019; responses to perceived health threats and their subsequent actions (<xref rid="ref26" ref-type="bibr">26</xref>). This model adapts to the context of disease and serves as an educational framework for understanding illness (<xref rid="ref27" ref-type="bibr">27</xref>). Within this model, illness perception comprises two active parallel processes: 1. Recognition and objective interpretation of the threat; and 2. The interaction between knowledge and feelings (<xref rid="ref28" ref-type="bibr">28</xref>). Each of these parallel processes consists of three stages (<xref rid="ref29" ref-type="bibr">29</xref>): 1. Representation; 2. Coping; 3. Appraisal.</p><p>Illness perception significantly influences quality of life and can affect treatment adherence and psychosocial responses. Furthermore, the perception of a disease can impact its symptoms and consequences, such as stress, anxiety, and depression (<xref rid="ref30" ref-type="bibr">30</xref>). According to this model, when patients adhere to the guidance and training provided to manage their condition, they develop a more accurate understanding of their illness, which in turn reduces the adverse consequences and mortality associated with the disease (<xref rid="ref31" ref-type="bibr">31</xref>). It is anticipated that enhancing illness perceptions among individuals with multiple sclerosis will mitigate the negative consequences of the condition, such as stress, anxiety, and depression. Consequently, this study aims to evaluate whether an intervention based on Leventhal&#x02019;s model can effectively reduce stress, anxiety, and depression in women with multiple sclerosis.</p></sec><sec sec-type="methods" id="sec6"><label>2</label><title>Methods</title><sec id="sec7"><label>2.1</label><title>Study type and design</title><p>The current study was conducted as a randomized educational trial involving women referred to the MS Association in Arak City in 2024. For this study, the Iranian Registry Clinical Trial code (IRCT) is IRCT20220703055351N3.</p></sec><sec id="sec8"><label>2.2</label><title>Participant selection</title><p>The inclusion criteria specified that participants must be women aged between 18 and 50, possess access to a smartphone, be literate, and demonstrate communication skills in reading, writing, speaking, and listening. Participants must have had at least one year since the initial onset of the disease. Additionally, their medical history should be free of any other neurological, mental, or autoimmune disorders, and they must not be experiencing any uncontrolled acute illnesses during their participation in the study. Furthermore, their condition should not have relapsed, and they must not be using any narcotic substances. Participants are required to achieve a maximum score of 5.5 on the expanded disability status scale and should not have undergone any training that aligns with the objectives of this research. Informed consent was obtained from all participants.</p><p>The exclusion criteria included reluctance to maintain collaboration, disease recurrence, hospitalization for illness or other reasons, or significant life changes such as relocation, unexpected illness, or pregnancy.</p></sec><sec id="sec9"><label>2.3</label><title>Sample size calculation</title><p>The sample size was determined based on information from previous studies (<xref rid="ref32" ref-type="bibr">32</xref>). With <italic>&#x003b1;</italic> set at 5% and <italic>&#x003b2;</italic> at 0.1, the following formula was applied:</p><disp-formula id="E1">
<mml:math id="M1" overflow="scroll"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mfrac><mml:mi>&#x003b1;</mml:mi><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mspace width="0.25em"/><mml:mo stretchy="true">(</mml:mo><mml:msup><mml:msub><mml:mi>s</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:msub><mml:mi>s</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mfrac></mml:math>
</disp-formula><p>The initial calculation indicated that 29 participants were required in both the control and experimental groups. To account for potential sample loss (10%), this number was increased to 32 participants per group, resulting in a total sample size of 64. During the research, four individuals were excluded, leaving a total of 60 participants. A convenience sampling method was employed. The Sealedenvelope website was utilized to generate a block random allocation list (<xref rid="ref33" ref-type="bibr">33</xref>). Randomization was concealed through centralized randomization. Following participant enrollment, the researcher informed participants via SMS and consulted with another researcher to determine the random allocation of participants (<xref rid="ref34" ref-type="bibr">34</xref>).</p></sec><sec id="sec10"><label>2.4</label><title>Intervention</title><p>This research introduced self-regulation training based on the Leventhal model. It comprised one in-person session for foundational knowledge, eight offline sessions for cognitive and emotional development, and two online group sessions for illness adaptation within one month. Virtual education included both synchronous (online) and asynchronous (offline) programs, with synchronous sessions held in groups and asynchronous sessions conducted individually.</p><p>The offline sessions incorporated multimedia elements, including podcasts, videos, and slides, which were uploaded to cloud storage (Dropbox). Links to each session were distributed via a Telegram group. The multimedia content addressed both the physical and emotional aspects of the disease. In collaboration with experts from various disciplines relevant to the disease&#x02019;s dimensions, the materials were meticulously crafted based on articles, books, and expert insights (<xref rid="tab1" ref-type="table">Table 1</xref>). The training was organized according to reliable scientific sources (<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref30" ref-type="bibr">30</xref>, <xref rid="ref35" ref-type="bibr">35&#x02013;54</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Explanation of intervention sessions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Session</th><th align="center" valign="top" rowspan="1" colspan="1">Week of sessions</th><th align="center" valign="top" rowspan="1" colspan="1">Delivery format (Online/Offline)</th><th align="center" valign="top" rowspan="1" colspan="1">Dimension of SMR</th><th align="center" valign="top" rowspan="1" colspan="1">Topic</th><th align="center" valign="top" rowspan="1" colspan="1">Description of the training</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" colspan="5" rowspan="1">The first session aimed to enhance participants&#x02019; understanding of the research, conduct a survey for selecting appropriate platforms, and provide training on utilizing educational content</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="2" colspan="1">First week</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Cognitive</td><td align="center" valign="top" rowspan="1" colspan="1">Identity</td><td align="center" valign="top" rowspan="1" colspan="1">Introduction of the disease, mechanism of development, and incidence statistics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Emotional</td><td align="center" valign="top" rowspan="1" colspan="1">Stress management</td><td align="center" valign="top" rowspan="1" colspan="1">Mechanism of stress, identification of stressors, relationship between stress and MS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="3" colspan="1">Second&#x0202f;week</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Cognitive</td><td align="center" valign="top" rowspan="1" colspan="1">Cause</td><td align="center" valign="top" rowspan="1" colspan="1">Explanation of the cause of the disease such as genetics, environmental factors, nutrition, lifestyle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Emotional</td><td align="center" valign="top" rowspan="1" colspan="1">Problem-solving</td><td align="center" valign="top" rowspan="1" colspan="1">Identifying the problem, generating solutions, evaluating solutions, prioritizing and choosing</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Peer groups</td><td align="center" valign="top" colspan="2" rowspan="1">To exchange the experiences of the participants, group discussion (with their peers)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="2" colspan="1">The third week</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Cognitive</td><td align="center" valign="top" rowspan="1" colspan="1">Timeline</td><td align="center" valign="top" rowspan="1" colspan="1">Introduction to the types of MS. Relapse and remission periods. Progression of the disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Emotional</td><td align="center" valign="top" rowspan="1" colspan="1">Anger control</td><td align="center" valign="top" rowspan="1" colspan="1">Identifying situations that cause anger, anger management techniques: leaving the place and</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="3" colspan="1">Fourth week</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Cognitive</td><td align="center" valign="top" rowspan="1" colspan="1">Controllability and consequences</td><td align="center" valign="top" rowspan="1" colspan="1">Consequences, signs and complications, how to control and reduce complications</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Emotional</td><td align="center" valign="top" rowspan="1" colspan="1">Depression management</td><td align="center" valign="top" rowspan="1" colspan="1">The mechanism of depression, identification of aggravating factors of depression, and the relationship between depression and MS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Offline</td><td align="center" valign="top" rowspan="1" colspan="1">Peer groups</td><td align="center" valign="top" colspan="2" rowspan="1">To exchange the experiences of the participants, group discussion (with their peers)</td></tr></tbody></table></table-wrap><p>The online group sessions were structured as peer groups to facilitate participant experience exchange. Participants were invited to engage in discussions with their peers and to create dynamic interactions with the researcher. Online sessions were conducted in a Telegram group.</p><p>The training was structured around the three stages of Leventhal&#x02019;s self-regulation model: 1. Representation, 2. Coping, and 3. Appraisal (<xref rid="fig1" ref-type="fig">Figure 1</xref>). It was designed to encompass both cognitive and emotional dimensions.</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Leventhal&#x02019;s self-regulation model.</p></caption><graphic xlink:href="fneur-16-1521112-g001" position="float"/></fig><sec id="sec11"><label>2.4.1</label><title>Representation</title><p>The objective is to develop a representation that effectively captures both cognitive and emotional dimensions. Within the cognitive domain, training encompasses five key dimensions: identity, cause, timeline, controllability, and consequences. This training was delivered to the experimental group via a multimedia link through Telegram every Monday. Given the interrelation between controllability and consequences regarding the disease, these two dimensions were consolidated and addressed in a single session to enhance understanding and monitoring of participants&#x02019; fatigue. Consequently, four offline virtual sessions were conducted weekly.</p><p>To assess the emotional requirements of individuals, a series of inquiries were employed to gauge emotional representation. The questions included: What is the primary challenge that MS has imposed on you? What are your greatest fears regarding MS? Among the primary emotional concerns identified were stress management, problem-solving, anger control, and depression management. Patients received weekly training two days following the cognitive training sessions.</p></sec><sec id="sec12"><label>2.4.2</label><title>Coping</title><p>Coping strategies were integrated into the representation, complemented by two online sessions held on Friday evenings aimed at fostering optimal coping levels. In each session, two participants who exhibited significant adaptation to the disease were invited to share their positive experiences. To evaluate adaptive responses, a customized checklist based on the Cognitive Emotional Regulation Questionnaire (CERQ) was utilized. The questions included: 1. I believe I must accept the situation that has occurred. 2. I think I need to learn to coexist with this negative experience. 3. I contemplate how I can manage the situation more effectively. Following the analysis of responses, individuals demonstrating the highest levels of acceptance of the disease, with informed consent, shared their experiences with other participants. Additionally, participants were encouraged to engage with researchers during the online sessions. The researchers facilitated discussions, promoting the sharing of experiences in a manner that fostered positive coping strategies. Real-time feedback was provided, and discussions were moderated to mitigate misinformation or distressing content.</p></sec><sec id="sec13"><label>2.4.3</label><title>Appraisal</title><p>To achieve this aim, researchers developed inquiries focused on both cognitive and emotional aspects. For instance: 1. What concerns you most about this illness? 2. Are you apprehensive about your recovery? After gathering feedback and evaluations, we resumed the instruction of the necessary content.</p><p>The control group did not receive any intervention during this period. Ethical considerations were upheld by offering training to the control group following the completion of the intervention.</p></sec></sec><sec id="sec14"><label>2.5</label><title>Instruments</title><p>In this study, data collection comprised two components: the demographic information form and the Depression Anxiety Stress Scale (DASS) questionnaire.</p><sec id="sec15"><label>2.5.1</label><title>Demographic information</title><p>This form collects essential information regarding the participant and their illness, including the duration of MS, the number of relapses in the past year, and the number of hospital admissions within the same timeframe, as well as age, occupation, education level, family income, marital status, health insurance, psychosocial support, urban or rural residency, and lifestyle (independent or living with family). To ensure the validity of the content within this questionnaire, it was reviewed by ten professors at the university, and their feedback was incorporated into the final version.</p></sec><sec id="sec16"><label>2.5.2</label><title>Depression Anxiety Stress Scale (DASS)</title><p>This questionnaire comprises 21 questions divided into three subscales measuring anxiety, stress, and depression, with each subscale containing 7 questions. It utilizes a 4-point Likert scale ranging from 0 (not at all) to 3 (very much), resulting in a score for each dimension that ranges from 0 to 21, where a higher score signifies more negative experiences (<xref rid="ref55" ref-type="bibr">55</xref>). The validity and reliability of this questionnaire were assessed in Sahibi et al.&#x02019;s (<xref rid="ref56" ref-type="bibr">56</xref>) research conducted in Iran, yielding satisfactory and significant reliability and validity coefficients. Consequently, the DASS-21 meets the necessary criteria for application in psychological research and clinical settings, including studies related to multiple sclerosis (<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref57" ref-type="bibr">57</xref>). Dependent variables were measured before, immediately after, and four weeks post-intervention in both the control and experimental groups. To comprehensively evaluate the cognitive and emotional responses of participants in accordance with Leventhal&#x02019;s Model, additional tools such as the Brief Illness Perception Questionnaire (BIPQ), the Cognitive Emotion Regulation Questionnaire (CERQ), and qualitative inquiries were utilized.</p></sec></sec><sec id="sec17"><label>2.6</label><title>Statistical analysis</title><p>Data analysis was performed using SPSS version 26.0, employing both descriptive statistics (means, standard deviations, frequencies, and percentages) and inferential statistics, including chi-square and Fisher&#x02019;s exact tests. The Kolmogorov&#x02013;Smirnov test was employed to assess data normality, confirming that the data were normally distributed. Independent t-tests and the equivalent nonparametric Mann&#x02013;Whitney tests were utilized to compare quantitative measures across groups. A repeated measures analysis of variance was conducted to evaluate changes over three time points, and the Bonferroni pairwise comparison test was applied to examine temporal changes.</p></sec><sec id="sec18"><label>2.7</label><title>Ethics statement</title><p>In December 2023, the ethics committee of the Arak University of Medical Sciences approved this research, assigning it the reference number IR.ARAKMU.REC.1402.199. Throughout the study, the moderators adhered to ethical considerations, including informed consent, confidentiality, the right to withdraw, and compensation for any potential harm.</p></sec></sec><sec sec-type="results" id="sec19"><label>3</label><title>Results</title><p>The present study aimed to evaluate the effects of training based on Leventhal&#x02019;s self-regulation model on anxiety, stress, and depression in women with multiple sclerosis, involving a total of 60 patients (31 in the control group and 29 in the experimental group). No statistically significant differences were observed between the control and experimental groups regarding age, sex, occupation, education, living situation (alone or with family), number of hospitalizations, number of relapses, urban or rural residence, insurance status, and support resources (<italic>p</italic> &#x0003e;&#x0202f;0.05). However, the marital status variable exhibited a significant difference between the two groups (<italic>p</italic> &#x0003c;&#x0202f;0.05), which was controlled in the analysis of variance with repeated measures. The average age of the patients was 37.75&#x0202f;&#x000b1;&#x0202f;6.44&#x0202f;years, ranging from 23&#x02013;50&#x0202f;years (<xref rid="tab2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Between-group comparisons of participants&#x02019; baseline characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="3" rowspan="2">Group Variable</th><th align="center" valign="top" colspan="2" rowspan="1">Group</th><th align="center" valign="top" rowspan="2" colspan="1"><italic>p</italic> value</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Control (<xref rid="ref31" ref-type="bibr">31</xref>) Mean&#x000b1;SD No (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Intervention (<xref rid="ref29" ref-type="bibr">29</xref>) Mean&#x000b1;SD No (%)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="3" rowspan="1">Age(years)</td><td align="center" valign="top" rowspan="1" colspan="1">5.63&#x0202f;&#x000b1;&#x0202f;37.87</td><td align="center" valign="top" rowspan="1" colspan="1">7.31&#x0202f;&#x000b1;&#x0202f;37.62</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> =&#x0202f;0.882<sup>a</sup></td></tr><tr><td align="left" valign="top" colspan="3" rowspan="1">Duration(years)</td><td align="center" valign="top" rowspan="1" colspan="1">6.2&#x0202f;&#x000b1;&#x0202f;8.87</td><td align="center" valign="top" rowspan="1" colspan="1">5.72&#x0202f;&#x000b1;&#x0202f;9.83</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> =&#x0202f;0.538<sup>a</sup></td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Marital status</td><td align="left" valign="top" rowspan="1" colspan="1">Divorced</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (13.8%)</td><td align="center" valign="top" rowspan="3" colspan="1"><italic>p</italic> =&#x0202f;0.007<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Single</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">2) 6.5%(</td><td align="center" valign="top" rowspan="1" colspan="1">9) 31%(</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Married</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">28) 90.3%(</td><td align="center" valign="top" rowspan="1" colspan="1">16) 55.2%(</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Occupation</td><td align="left" valign="top" rowspan="1" colspan="1">Employed</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (74.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (69%)</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>p</italic> =&#x0202f;0.653<sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Housewife</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (31%)</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">Education</td><td align="left" valign="top" rowspan="1" colspan="1">Undereducated</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.4%)</td><td align="center" valign="top" rowspan="4" colspan="1"><italic>p</italic> =&#x0202f;0.606<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Under diploma</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diploma</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (35.5)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (37.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">University</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (58.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (58.6%)</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Who life</td><td align="left" valign="top" rowspan="1" colspan="1">Alone</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.9%)</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>p</italic> =&#x0202f;0.229<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (100%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (93.1%)</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Hospitalization How many times have you been admitted to the hospital over the last year?</td><td align="left" valign="top" rowspan="1" colspan="1">Without</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (71%)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (55.2%)</td><td align="center" valign="top" rowspan="3" colspan="1"><italic>p</italic> =&#x0202f;0.528<sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Once</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (24.1%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">More than once</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (12.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (20.7%)</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Recurrence: How many times has your illness recurred in the past year?</td><td align="left" valign="top" rowspan="1" colspan="1">Without</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (87.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (82.8%)</td><td align="center" valign="top" rowspan="3" colspan="1"><italic>p</italic> =&#x0202f;0.576<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Twice</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (10.3%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">More than twice</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.9%)</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Living: What is the location of your residence?</td><td align="left" valign="top" rowspan="1" colspan="1">Village</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>p</italic> =&#x0202f;0.999<sup>c</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">City</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (96.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (100%)</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Insurance: Do you have health insurance?</td><td align="left" valign="top" rowspan="1" colspan="1">Without</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.4%)</td><td align="center" valign="top" rowspan="2" colspan="1">P&#x0202f;=&#x0202f;0.999<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">With</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (96.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (96.6%)</td></tr><tr><td align="left" valign="top" rowspan="5" colspan="1">Support: What support system do you have?</td><td align="left" valign="top" rowspan="1" colspan="1">No support</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="5" colspan="1"><italic>p</italic> =&#x0202f;0.166<sup>b</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MS Association</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (25.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (27.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Friends Support</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (22.6%)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (27.6%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family support</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">all</td><td align="left" valign="top" rowspan="1" colspan="1">(%)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (35.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (44.8%)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Independent t test; <sup>b</sup>Fisher&#x02019;s exact test; <sup>c</sup>Chi-square test.</p></table-wrap-foot></table-wrap><p>Results indicated that prior to the intervention, the mean scores for depression, anxiety, and stress were not significantly different between the two groups (<italic>p</italic> &#x0003e;&#x0202f;0.05). However, the average scores for depression, anxiety, and stress after the intervention and one-month post-intervention were significantly different between the control and experimental groups (<italic>p</italic> &#x0003c;&#x0202f;0.05).</p><p>To investigate the trend of changes in stress, anxiety, and depression over three time points, a repeated measures analysis of variance was conducted, controlling for confounding effects such as marital status. The results indicated that the average changes in stress, anxiety, and depression across all samples were not significant (<italic>p</italic> &#x0003e;&#x0202f;0.05). However, the interaction effect between time and group was significant (<italic>p</italic> &#x0003c;&#x0202f;0.05), which means that there was a significant difference in time changes between the groups. In other words, the trends in the average stress, anxiety and depression in the two groups over time were significantly different (<xref rid="tab3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Comparison of the mean and standard deviation changes in depression, anxiety and stress.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Variable</th><th align="center" valign="top" rowspan="2" colspan="1">Groups</th><th align="center" valign="top" rowspan="2" colspan="1">T1 Mean&#x000b1;SD</th><th align="center" valign="top" rowspan="2" colspan="1">T2 Mean&#x000b1;SD</th><th align="center" valign="top" rowspan="2" colspan="1">T3 Mean&#x000b1;SD</th><th align="center" valign="top" rowspan="2" colspan="1">Mean&#x000b1;SD</th><th align="center" valign="top" colspan="3" rowspan="1">Analysis of variance with repeated measures</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Within-subject</th><th align="center" valign="top" rowspan="1" colspan="1">Between-group</th><th align="center" valign="top" rowspan="1" colspan="1">Time group</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1">Stress</td><td align="center" valign="middle" rowspan="1" colspan="1">Intervention</td><td align="center" valign="top" rowspan="1" colspan="1">5.57 &#x000b1; 8.55</td><td align="center" valign="top" rowspan="1" colspan="1">4.55 &#x000b1; 4.93</td><td align="center" valign="top" rowspan="1" colspan="1">4.38 &#x000b1; 5.51</td><td align="center" valign="top" rowspan="1" colspan="1">0.870 &#x000b1; 6.075</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;0.066<break/><italic>p</italic> =&#x0202f;0.803</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;14.850<break/>p&#x0202f;=&#x0202f;0.0001</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic>&#x0202f;=&#x0202f;6.839<break/><italic>p</italic>&#x0202f;=&#x0202f;0.011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">4.97 &#x000b1; 11.09</td><td align="center" valign="top" rowspan="1" colspan="1">5.10 &#x000b1; 10.35</td><td align="center" valign="top" rowspan="1" colspan="1">5.02 &#x000b1; 10.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.840 &#x000b1; 10.866</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Anxiety</td><td align="center" valign="middle" rowspan="1" colspan="1">Intervention</td><td align="center" valign="top" rowspan="1" colspan="1">4.34 &#x000b1; 4.89</td><td align="center" valign="top" rowspan="1" colspan="1">2.48 &#x000b1; 1.96</td><td align="center" valign="top" rowspan="1" colspan="1">2.31 &#x000b1; 2.93</td><td align="center" valign="top" rowspan="1" colspan="1">3.054 &#x000b1; 0.746</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;0.717<break/><italic>p</italic> =&#x0202f;0.491</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;19.470<break/><italic>p</italic> =&#x0202f;0.0001</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic>&#x0202f;=&#x0202f;13.320<break/><italic>P</italic>&#x0202f;=&#x0202f;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">5.34 &#x000b1; 7.06</td><td align="center" valign="top" rowspan="1" colspan="1">4.98 &#x000b1; 7.70</td><td align="center" valign="top" rowspan="1" colspan="1">4.94 &#x000b1; 7.90</td><td align="center" valign="top" rowspan="1" colspan="1">7.756 &#x000b1; 0.720</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Depression</td><td align="center" valign="middle" rowspan="1" colspan="1">Intervention</td><td align="center" valign="top" rowspan="1" colspan="1">4.26&#x0202f;&#x000b1;&#x0202f;6.82</td><td align="center" valign="top" rowspan="1" colspan="1">3.73&#x0202f;&#x000b1;&#x0202f;4.37</td><td align="center" valign="top" rowspan="1" colspan="1">3.61&#x0202f;&#x000b1;&#x0202f;4.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.803&#x0202f;&#x000b1;&#x0202f;5.013</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;2.387<break/><italic>p</italic> =&#x0202f;0.127</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic> =&#x0202f;11.769<break/><italic>p</italic> =&#x0202f;0.001</td><td align="center" valign="top" rowspan="2" colspan="1"><italic>F</italic>&#x0202f;=&#x0202f;10.604<break/><italic>P</italic>&#x0202f;=&#x0202f;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">5.33&#x0202f;&#x000b1;&#x0202f;8.61</td><td align="center" valign="top" rowspan="1" colspan="1">5.06&#x0202f;&#x000b1;&#x0202f;8.64</td><td align="center" valign="top" rowspan="1" colspan="1">4.88&#x0202f;&#x000b1;&#x0202f;8.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.775&#x0202f;&#x000b1;&#x0202f;8.945</td></tr></tbody></table><table-wrap-foot><p>T1, before intervention; T2, after intervention; T3, one month after the intervention.</p></table-wrap-foot></table-wrap><sec id="sec20"><label>3.1</label><title>Anxiety</title><p>As presented in <xref rid="tab4" ref-type="table">Table 4</xref>, the experimental group experienced a significant decrease in average anxiety scores following the intervention compared to pre-intervention levels (<italic>p</italic> &#x0003c;&#x0202f;0.05), but one month after the intervention, the average anxiety score increased significantly (<italic>p</italic> &#x0003c;&#x0202f;0.05). In the control group, there was no significant difference in average anxiety scores following the intervention (<italic>p</italic> &#x0003e;&#x0202f;0.05). Similar to the experimental group, the control group also exhibited a significant increase in anxiety levels one month after the intervention compared to post-intervention scores (<italic>p</italic> &#x0003c;&#x0202f;0.05).</p><table-wrap position="float" id="tab4"><label>Table 4</label><caption><p>Results of paired comparisons of the means and standard deviations of depression, anxiety and stress over time across groups (Bonferroni <italic>post hoc</italic> correction).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" rowspan="2" colspan="1">Variable</th><th align="center" valign="top" rowspan="2" colspan="1">Group</th><th align="center" valign="top" rowspan="2" colspan="1">Time</th><th align="center" valign="top" colspan="3" rowspan="1">Control</th><th align="center" valign="top" colspan="3" rowspan="1">Intervention</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Standard deviation</th><th align="center" valign="top" rowspan="1" colspan="1">Comparison of mean</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">Standard deviation</th><th align="center" valign="top" rowspan="1" colspan="1">Comparison of mean</th><th align="center" valign="top" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="3" colspan="1">Stress</td><td align="center" valign="top" rowspan="2" colspan="1">Before (T1)</td><td align="center" valign="top" rowspan="1" colspan="1">After (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.236</td><td align="center" valign="top" rowspan="1" colspan="1">0.742</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td><td align="center" valign="top" rowspan="1" colspan="1">1.038</td><td align="center" valign="top" rowspan="1" colspan="1">3.621</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.243</td><td align="center" valign="top" rowspan="1" colspan="1">0.677</td><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td align="center" valign="top" rowspan="1" colspan="1">1.065</td><td align="center" valign="top" rowspan="1" colspan="1">3.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">After intervention (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.045</td><td align="center" valign="top" rowspan="1" colspan="1">0.065-</td><td align="center" valign="top" rowspan="1" colspan="1">0.482</td><td align="center" valign="top" rowspan="1" colspan="1">0.127</td><td align="center" valign="top" rowspan="1" colspan="1">0.586-</td><td align="center" valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="top" rowspan="3" colspan="1">Anxiety</td><td align="center" valign="top" rowspan="2" colspan="1">Before (T1)</td><td align="center" valign="top" rowspan="1" colspan="1">After (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.414</td><td align="center" valign="top" rowspan="1" colspan="1">0.645-</td><td align="center" valign="top" rowspan="1" colspan="1">0.388</td><td align="center" valign="top" rowspan="1" colspan="1">0.893</td><td align="center" valign="top" rowspan="1" colspan="1">2.931</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.399</td><td align="center" valign="top" rowspan="1" colspan="1">0.839-</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td><td align="center" valign="top" rowspan="1" colspan="1">0.857</td><td align="center" valign="top" rowspan="1" colspan="1">1.966</td><td align="center" valign="top" rowspan="1" colspan="1">0.089</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">After intervention (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.072</td><td align="center" valign="top" rowspan="1" colspan="1">0.194-</td><td align="center" valign="top" rowspan="1" colspan="1">0.035</td><td align="center" valign="top" rowspan="1" colspan="1">0.136</td><td align="center" valign="top" rowspan="1" colspan="1">0.966-</td><td align="center" valign="top" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="top" rowspan="3" colspan="1">Depression</td><td align="center" valign="top" rowspan="2" colspan="1">Before (T1)</td><td align="center" valign="top" rowspan="1" colspan="1">After (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.378</td><td align="center" valign="top" rowspan="1" colspan="1">0.032-</td><td align="center" valign="top" rowspan="1" colspan="1">0.999</td><td align="center" valign="top" rowspan="1" colspan="1">0.846</td><td align="center" valign="top" rowspan="1" colspan="1">2.448</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.347</td><td align="center" valign="top" rowspan="1" colspan="1">0.161-</td><td align="center" valign="top" rowspan="1" colspan="1">0.999</td><td align="center" valign="top" rowspan="1" colspan="1">0.855</td><td align="center" valign="top" rowspan="1" colspan="1">2.138</td><td align="center" valign="top" rowspan="1" colspan="1">0.056</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">After intervention (T2)</td><td align="center" valign="top" rowspan="1" colspan="1">One month after (T3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.077</td><td align="center" valign="top" rowspan="1" colspan="1">0.129-</td><td align="center" valign="top" rowspan="1" colspan="1">0.310</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td><td align="center" valign="top" rowspan="1" colspan="1">0.310-</td><td align="center" valign="top" rowspan="1" colspan="1">0.079</td></tr></tbody></table><table-wrap-foot><p>T1, before intervention; T2, after intervention; T3, one month after the intervention.</p></table-wrap-foot></table-wrap></sec><sec id="sec21"><label>3.2</label><title>Stress</title><p>The analysis revealed significant differences in average stress changes over time between the two groups. Both the experimental and control groups showed a significant decrease in average stress levels after the intervention and one-month post-intervention compared to pre-intervention levels (<italic>p</italic> &#x0003c;&#x0202f;0.05). However, in the experimental group, there was a significant increase in average stress levels one month after the intervention compared to post-intervention levels (p&#x0202f;&#x0003c;&#x0202f;0.05).</p></sec><sec id="sec22"><label>3.3</label><title>Depression</title><p>In the experimental group, the average depression score decreased significantly after the intervention compared to pre-intervention levels (p&#x0202f;&#x0003c;&#x0202f;0.05). At subsequent evaluation points, no significant changes were observed (<italic>p</italic> &#x0003e;&#x0202f;0.05). In the control group, there were no significant differences in average depression scores across the evaluation periods (p&#x0202f;&#x0003e;&#x0202f;0.05).</p></sec></sec><sec sec-type="discussion" id="sec23"><label>4</label><title>Discussion</title><p>This study examined the efficacy of Leventhal&#x02019;s self-regulation model in alleviating stress, anxiety, and depression among female patients with multiple sclerosis (MS). The results indicated significant enhancements in psychological outcomes immediately post-intervention; however, the sustainability of these effects differed across various psychological domains over time.</p><sec id="sec24"><label>4.1</label><title>Anxiety</title><p>The experimental group demonstrated a significant reduction in anxiety immediately after the intervention (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05). However, one month later, anxiety levels significantly increased (p&#x0202f;&#x0003c;&#x0202f;0.05), indicating that the intervention&#x02019;s effect was not maintained long-term. In contrast, the control group showed no significant change in anxiety levels, except for a significant increase one month after the intervention (p&#x0202f;&#x0003c;&#x0202f;0.05). These results suggest that while the intervention produced initial efficacy, supplementary strategies may be necessary to sustain its benefits. Previous research has shown that psychological interventions based on the illness perception framework, including the Leventhal model, can effectively reduce anxiety (<xref rid="ref58" ref-type="bibr">58</xref>, <xref rid="ref59" ref-type="bibr">59</xref>). Similarly, the intergroup comparison confirmed a significant intervention effect on anxiety reduction. Specifically, no significant difference was observed before the intervention (<italic>p</italic>&#x0202f;&#x0003e;&#x0202f;0.05), but after the intervention and at the one-month follow-up, the experimental group presented significantly lower anxiety levels than did the control group (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05). These findings align with previous research demonstrating an inverse relationship between illness perception and anxiety levels (<xref rid="ref60" ref-type="bibr">60</xref>).</p></sec><sec id="sec25"><label>4.2</label><title>Depression</title><p>The experimental group showed a significant decrease in depressive symptoms after the intervention (p&#x0202f;&#x0003c;&#x0202f;0.05), and this improvement persisted at the one-month follow-up. In contrast, the control group showed an increasing trend in depressive symptoms over time, although this change was not statistically significant. Depression is a common concern among patients with MS (<xref rid="ref61" ref-type="bibr">61</xref>) and is often associated with the unpredictability of the disease and uncertainty about prognosis (<xref rid="ref62" ref-type="bibr">62</xref>). Given that the intervention enhanced both the cognitive and physical aspects of illness perception, it is plausible that it contributed to a better understanding of the disease course and, consequently, a reduction in depressive symptoms. These results are consistent with previous research that emphasized the role of illness perception interventions in reducing depression in populations with chronic illnesses (<xref rid="ref63" ref-type="bibr">63</xref>, <xref rid="ref64" ref-type="bibr">64</xref>).</p></sec><sec id="sec26"><label>4.3</label><title>Stress</title><p>Both groups presented a significant reduction in stress after the intervention (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05), but this decrease was not sustained over time in the experimental group. Interestingly, stress levels also decreased in the control group, suggesting that factors such as participant expectations or the study design might have influenced these outcomes. Previous research underscores that predictability and perceived autonomy significantly impact stress levels (<xref rid="ref65" ref-type="bibr">65</xref>), a phenomenon that may explain the observed reductions in both cohorts. Nevertheless, additional longitudinal evaluations are imperative to ascertain whether the intervention yields enduring effects. Collectively, these results bolster the validity of Leventhal&#x02019;s theoretical framework in enhancing psychological well-being among individuals with chronic ailments (<xref rid="ref66" ref-type="bibr">66</xref>, <xref rid="ref67" ref-type="bibr">67</xref>). However, some investigations have yielded inconclusive outcomes, suggesting that supplementary behavioral or spiritual strategies may be required for sustained benefits (<xref rid="ref68" ref-type="bibr">68</xref>). The discrepancies in the findings across these studies may be attributed to variations in the nature of the diverse diseases examined. Furthermore, differences in illness perceptions may influence other outcomes. Specifically, illness perception can affect treatment adherence and psychosocial responses, thereby impacting disease-related symptoms and outcomes such as stress, anxiety, and depression (<xref rid="ref30" ref-type="bibr">30</xref>).</p></sec><sec id="sec27"><label>4.4</label><title>Conclusion</title><p>This research analyzed the effectiveness of Leventhal&#x02019;s self-regulation model in reducing anxiety, stress, and depression in women diagnosed with MS. Although the intervention significantly improved psychological outcomes in the short term, its long-term sustainability remains a subject of debate. Both anxiety and stress improved immediately after the intervention but increased again after one month. The reduction in depression, however, remained stable over time.The results highlight the model&#x02019;s strength in altering illness perceptions, particularly for depression, likely due to its support for cognitive restructuring and emotional adaptation. However, the temporary nature of anxiety and stress reduction points to the need for more comprehensive and sustained interventions. Despite its advantages, this intervention alone may prove inadequate for long-term psychological management in individuals with MS.</p><p>Future investigations should examine multimodal strategies, such as the integration of self-regulation training with cognitive&#x02013;behavioral therapy (CBT), mindfulness-based interventions, or pharmacological treatments, to increase its overall effectiveness. Furthermore, long-term follow-up assessments are imperative to ascertain the persistence of its effects and to refine intervention methodologies conducive to sustainable mental health enhancements. Additional research should prioritize individualized intervention frameworks and the incorporation of digital or telehealth adaptations to improve accessibility and adherence.</p></sec></sec></body><back><ack><p>We would like to thank all the patients who participated in this study.</p></ack><sec sec-type="data-availability" id="sec28"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p></sec><sec sec-type="ethics-statement" id="sec29"><title>Ethics statement</title><p>The studies involving humans were approved by on December 2023, the ethics committee of Arak University of Medical Sciences approved the current research, and assigned the reference number IR.ARAKMU.REC.1402.199. During the study, the moderators considered ethical aspects such as informed consent, confidentiality, withdrawal rights, and compensation for any potential harm. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec30"><title>Author contributions</title><p>MH: Conceptualization, Writing &#x02013; original draft. SS: Conceptualization, Methodology, Supervision, Project administration, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. AJ: Writing &#x02013; review &#x00026; editing. FR: Data curation, Software, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec32"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</p></sec><sec sec-type="ai-statement" id="sec33"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec34"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Geurts</surname><given-names>J</given-names></name><name><surname>Hemmer</surname><given-names>B</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name></person-group>. <article-title>Multiple sclerosis</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>391</volume>:<fpage>1622</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30481-1</pub-id>, PMID: <pub-id pub-id-type="pmid">29576504</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Walton</surname><given-names>C</given-names></name><name><surname>King</surname><given-names>R</given-names></name><name><surname>Rechtman</surname><given-names>L</given-names></name><name><surname>Kaye</surname><given-names>W</given-names></name><name><surname>Leray</surname><given-names>E</given-names></name><name><surname>Marrie</surname><given-names>RA</given-names></name><etal/></person-group>., <source>Rising prevalence of multiple sclerosis worldwide: Insights from the atlas of MS</source> (<edition>3rd Edn.</edition>). <publisher-name>Mult Scler</publisher-name>. (<year>2020</year>);<volume>26</volume>:<fpage>1816</fpage>&#x02013;<lpage>1821</lpage>. doi: <pub-id pub-id-type="doi">10.1177/135245852097084</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirmosayyeb</surname><given-names>O</given-names></name><name><surname>Shaygannejad</surname><given-names>V</given-names></name><name><surname>Bagherieh</surname><given-names>S</given-names></name><name><surname>Hosseinabadi</surname><given-names>AM</given-names></name><name><surname>Ghajarzadeh</surname><given-names>M</given-names></name></person-group>. <article-title>Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis</article-title>. <source>Neurol Sci</source>. (<year>2022</year>) <volume>43</volume>:<fpage>233</fpage>&#x02013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-021-05750-w</pub-id>, PMID: <pub-id pub-id-type="pmid">34787755</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>PK</given-names></name></person-group>. <article-title>What can we learn from sex differences in MS?</article-title>
<source>J Pers Med</source>. (<year>2021</year>) <volume>11</volume>:1006. doi: <pub-id pub-id-type="doi">10.3390/jpm11101006</pub-id>, PMID: <pub-id pub-id-type="pmid">34683148</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>Z</given-names></name><name><surname>Almasi-Hashiani</surname><given-names>A</given-names></name><name><surname>Sahraian</surname><given-names>MA</given-names></name><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Baghbanian</surname><given-names>SM</given-names></name><name><surname>Razazian</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Epidemiology of familial multiple sclerosis in Iran: a national registry-based study</article-title>. <source>BMC Neurol</source>. (<year>2022</year>) <volume>22</volume>:<fpage>76</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12883-022-02609-1</pub-id>, PMID: <pub-id pub-id-type="pmid">35248009</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>BE</given-names></name><name><surname>Lakin</surname><given-names>L</given-names></name><name><surname>Binns</surname><given-names>CC</given-names></name><name><surname>Currie</surname><given-names>KM</given-names></name><name><surname>Rensel</surname><given-names>MR</given-names></name></person-group>. <article-title>Patient and provider insights into the impact of multiple sclerosis on mental health: a narrative review</article-title>. <source>Neurol Ther</source>. (<year>2021</year>) <volume>10</volume>:<fpage>99</fpage>&#x02013;<lpage>119</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40120-021-00240-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33877584</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menculini</surname><given-names>G</given-names></name><name><surname>Mancini</surname><given-names>A</given-names></name><name><surname>Gaetani</surname><given-names>L</given-names></name><name><surname>Bellingacci</surname><given-names>L</given-names></name><name><surname>Tortorella</surname><given-names>A</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2023</year>) <volume>94</volume>:<fpage>389</fpage>&#x02013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2022-329806</pub-id>, PMID: <pub-id pub-id-type="pmid">36653171</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>F</given-names></name><name><surname>Leone</surname><given-names>C</given-names></name><name><surname>D'Amico</surname><given-names>E</given-names></name></person-group>. <article-title>Treatment options of cognitive impairment in multiple sclerosis</article-title>. <source>Neurol Sci</source>. (<year>2010</year>) <volume>31</volume>:<fpage>265</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-010-0438-7</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrie</surname><given-names>RA</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>Yu</surname><given-names>BN</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Elliott</surname><given-names>L</given-names></name><name><surname>Caetano</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance</article-title>. <source>BMC Neurol</source> (<year>2013</year>);<volume>13</volume>:<fpage>16</fpage>, doi: <pub-id pub-id-type="doi">10.1186/1471-2377-13-16</pub-id>, PMID: , PMCID: <!--<pub-id pub-id-type="pmcid">PMC3599013</pub-id>-->.<pub-id pub-id-type="pmid">23388102</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostolaza</surname><given-names>A</given-names></name><name><surname>Corroza</surname><given-names>J</given-names></name><name><surname>Ayuso</surname><given-names>T</given-names></name></person-group>. <article-title>Multiple sclerosis and aging: comorbidity and treatment challenges</article-title>. <source>Mult Scler Relat Disord</source>. (<year>2021</year>) <volume>50</volume>:<fpage>102815</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.msard.2021.102815</pub-id>, PMID: <pub-id pub-id-type="pmid">33581613</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>S</given-names></name><name><surname>Andayeshgar</surname><given-names>B</given-names></name><name><surname>Khatony</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence of anxiety, depression, and stress in patients with multiple sclerosis in Kermanshah-Iran: a cross-sectional study</article-title>. <source>BMC Psychiatry</source>. (<year>2020</year>) <volume>20</volume>:<fpage>166</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12888-020-02579-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32295564</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magyari</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>PS</given-names></name></person-group>. <article-title>Comorbidity in multiple sclerosis</article-title>. <source>Front Neurol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>851</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2020.00851</pub-id>, PMID: <pub-id pub-id-type="pmid">32973654</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peres</surname><given-names>DS</given-names></name><name><surname>Rodrigues</surname><given-names>P</given-names></name><name><surname>Viero</surname><given-names>FT</given-names></name><name><surname>Frare</surname><given-names>JM</given-names></name><name><surname>Kudsi</surname><given-names>SQ</given-names></name><name><surname>Meira</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis</article-title>. <source>Brain Behav Immun Health.</source> (<year>2022</year>) <volume>24</volume>:<fpage>100484</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbih.2022.100484</pub-id>, PMID: <pub-id pub-id-type="pmid">35856061</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafiee</surname><given-names>A</given-names></name><name><surname>Soltani</surname><given-names>H</given-names></name><name><surname>Teymouri Athar</surname><given-names>MM</given-names></name><name><surname>Jafarabady</surname><given-names>K</given-names></name><name><surname>Mardi</surname><given-names>P</given-names></name></person-group>. <article-title>The prevalence of depression and anxiety among Iranian people with multiple sclerosis: a systematic review and meta-analysis</article-title>. <source>Mult Scler Relat Disord</source>. (<year>2023</year>) <volume>78</volume>:<fpage>104922</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.msard.2023.104922</pub-id>, PMID: <pub-id pub-id-type="pmid">37597350</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briones-Buixassa</surname><given-names>L</given-names></name><name><surname>Monta&#x000f1;&#x000e9;s-Masias</surname><given-names>B</given-names></name><name><surname>Mil&#x000e0;-Villaroel</surname><given-names>R</given-names></name><name><surname>Arrufat</surname><given-names>FX</given-names></name><name><surname>Aragon&#x000e8;s</surname><given-names>JM</given-names></name><name><surname>Norton</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The bidirectional effect of stress and functionality in multiple sclerosis and the interaction role of anxiety, coping and social support</article-title>. <source>J Psychosom Res</source>. (<year>2023</year>) <volume>170</volume>:<fpage>111375</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychores.2023.111375</pub-id>, PMID: <pub-id pub-id-type="pmid">37196585</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauil</surname><given-names>CB</given-names></name><name><surname>da Rocha Lima</surname><given-names>AD</given-names></name><name><surname>Ferrari</surname><given-names>BB</given-names></name><name><surname>da Silva</surname><given-names>VAG</given-names></name><name><surname>Moraes</surname><given-names>AS</given-names></name><name><surname>da Silva</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines</article-title>. <source>Brain Behav Immun Health</source>. (<year>2020</year>) <volume>9</volume>:<fpage>100162</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbih.2020.100162</pub-id>, PMID: <pub-id pub-id-type="pmid">34589900</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;ksel Karatepe</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>T</given-names></name><name><surname>G&#x000fc;naydn</surname><given-names>R</given-names></name><name><surname>Demirhan</surname><given-names>A</given-names></name><name><surname>Ce</surname><given-names>P</given-names></name><name><surname>Gedizlio&#x0011f;lu</surname><given-names>M</given-names></name></person-group>. <article-title>Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability</article-title>. <source>Int J Rehabil Res</source>. (<year>2011</year>) <volume>34</volume>:<fpage>290</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MRR.0b013e32834ad479</pub-id>, PMID: <pub-id pub-id-type="pmid">21946317</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solaro</surname><given-names>C</given-names></name><name><surname>Gamberini</surname><given-names>G</given-names></name><name><surname>Masuccio</surname><given-names>FG</given-names></name></person-group>. <article-title>Depression in multiple sclerosis: epidemiology, etiology</article-title>. <source>Diagnosis Treatment CNS Drugs</source>. (<year>2018</year>) <volume>32</volume>:<fpage>117</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40263-018-0489-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29417493</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f3;&#x0017c;ycka</surname><given-names>J</given-names></name></person-group>. <article-title>How I see is how I feel. Identification of illness perception schema and its association with adaptation outcomes in multiple sclerosis - a 5-year prospective study</article-title>. <source>PLoS One</source>. (<year>2021</year>) <volume>16</volume>:<fpage>e0258740</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0258740</pub-id>, PMID: <pub-id pub-id-type="pmid">34710124</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>M</given-names></name><name><surname>Howell</surname><given-names>D</given-names></name><name><surname>McCorry</surname><given-names>NK</given-names></name></person-group>. <article-title>Illness perceptions and coping in physical health conditions: a meta-analysis</article-title>. <source>J Psychosom Res</source>. (<year>2015</year>) <volume>79</volume>:<fpage>506</fpage>&#x02013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychores.2015.10.006</pub-id>, PMID: <pub-id pub-id-type="pmid">26541550</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maryam</surname><given-names>J</given-names></name><name><surname>Tahereh</surname><given-names>A</given-names></name><name><surname>Zhila</surname><given-names>A</given-names></name><name><surname>Hamid</surname><given-names>A</given-names></name></person-group>. <article-title>Promotion of illness perception and it is aspects in a multiple sclerosis (MS) peer support groups</article-title>. <source>J Knowledge Health</source>. (<year>2013</year>) <volume>8</volume>:<fpage>24</fpage>. doi: <pub-id pub-id-type="doi">10.22100/jkh.v8i1.40</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davari</surname><given-names>S</given-names></name><name><surname>Boogar</surname><given-names>IR</given-names></name><name><surname>Talepasand</surname><given-names>S</given-names></name><name><surname>Evazi</surname><given-names>MR</given-names></name></person-group>. <article-title>The effect of religious-spiritual psychotherapy on illness perception and inner strength among patients with breast Cancer in Iran</article-title>. <source>J Relig Health</source>. (<year>2022</year>) <volume>61</volume>:<fpage>4302</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10943-022-01594-6</pub-id>, PMID: <pub-id pub-id-type="pmid">35690697</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budiono</surname><given-names>W</given-names></name><name><surname>Kantono</surname><given-names>K</given-names></name><name><surname>Kristianto</surname><given-names>FC</given-names></name><name><surname>Avanti</surname><given-names>C</given-names></name><name><surname>Herawati</surname><given-names>F</given-names></name></person-group>. <article-title>Psychoeducation improved illness perception and expressed emotion of family caregivers of patients with schizophrenia</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2021</year>) <volume>18</volume>:7522. doi: <pub-id pub-id-type="doi">10.3390/ijerph18147522</pub-id>, PMID: <pub-id pub-id-type="pmid">34299972</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalili</surname><given-names>Z</given-names></name><name><surname>Bayazi</surname><given-names>MH</given-names></name></person-group>. <article-title>The effectiveness of mindfulness-based cognitive therapy on the illness perception and psychological symptoms in patients with rheumatoid arthritis</article-title>. <source>Complement Ther Clin Pract</source>. (<year>2019</year>) <volume>34</volume>:<fpage>139</fpage>&#x02013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ctcp.2018.11.012</pub-id>, PMID: <pub-id pub-id-type="pmid">30712718</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosi</surname><given-names>C</given-names></name><name><surname>Zaiontz</surname><given-names>C</given-names></name><name><surname>Peragine</surname><given-names>G</given-names></name><name><surname>Sarchi</surname><given-names>S</given-names></name><name><surname>Bona</surname><given-names>F</given-names></name></person-group>. <article-title>Randomized controlled study on the effectiveness of animal-assisted therapy on depression, anxiety, and illness perception in institutionalized elderly</article-title>. <source>Psychogeriatrics</source>. (<year>2019</year>) <volume>19</volume>:<fpage>55</fpage>&#x02013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1111/psyg.12367</pub-id>, PMID: <pub-id pub-id-type="pmid">30221438</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagger</surname><given-names>MS</given-names></name><name><surname>Orbell</surname><given-names>S</given-names></name></person-group>. <article-title>The common sense model of illness self-regulation: a conceptual review and proposed extended model</article-title>. <source>Health Psychol Rev</source>. (<year>2022</year>) <volume>16</volume>:<fpage>347</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1080/17437199.2021.1878050</pub-id>, PMID: <pub-id pub-id-type="pmid">33461402</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>AJ</given-names></name><name><surname>Wiebe</surname><given-names>JS</given-names></name><name><surname>Edwards</surname><given-names>DL</given-names></name><name><surname>Michels</surname><given-names>JD</given-names></name><name><surname>Lawton</surname><given-names>WJ</given-names></name></person-group>. <article-title>Body consciousness, illness-related impairment, and patient adherence in hemodialysis</article-title>. <source>J Consult Clin Psychol</source>. (<year>1996</year>) <volume>64</volume>:<fpage>147</fpage>&#x02013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1037/0022-006X.64.1.147</pub-id>, PMID: <pub-id pub-id-type="pmid">8907094</pub-id>
</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leventhal</surname><given-names>H</given-names></name></person-group>. <article-title>The common sense representation of illness danger</article-title>. <source>Contrib Med Psychol</source>. (<year>1980</year>):<fpage>7</fpage>.</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>RL</given-names></name><name><surname>Rankin</surname><given-names>SH</given-names></name></person-group>. <article-title>Application of Leventhal's self-regulation model to Chinese immigrants with type 2 diabetes</article-title>. <source>J Nurs Scholarsh</source>. (<year>2001</year>) <volume>33</volume>:<fpage>53</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1547-5069.2001.00053.x</pub-id>, PMID: <pub-id pub-id-type="pmid">11253580</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Filippis</surname><given-names>S</given-names></name><name><surname>Erbuto</surname><given-names>D</given-names></name><name><surname>Gentili</surname><given-names>F</given-names></name><name><surname>Innamorati</surname><given-names>M</given-names></name><name><surname>Lester</surname><given-names>D</given-names></name><name><surname>Tatarelli</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache</article-title>. <source>J Headache Pain</source> (<year>2008</year>);<volume>9</volume>:<fpage>349</fpage>&#x02013;<lpage>357</lpage>, doi: <pub-id pub-id-type="doi">10.1007/s10194-008-0072-4</pub-id>, PMID: , PMCID: <!--<pub-id pub-id-type="pmcid">PMC3452079</pub-id>-->.<pub-id pub-id-type="pmid">18953488</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAndrew</surname><given-names>LM</given-names></name><name><surname>Horowitz</surname><given-names>CR</given-names></name><name><surname>Lancaster</surname><given-names>KJ</given-names></name><name><surname>Leventhal</surname><given-names>H</given-names></name></person-group>. <article-title>Factors related to perceived diabetes control are not related to actual glucose control for minority patients with diabetes</article-title>. <source>Diabetes Care</source>. (<year>2010</year>) <volume>33</volume>:<fpage>736</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc09-1229</pub-id>, PMID: <pub-id pub-id-type="pmid">20067972</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khodaparast</surname><given-names>S</given-names></name><name><surname>Soleimani</surname><given-names>MA</given-names></name><name><surname>Bahrami</surname><given-names>N</given-names></name><name><surname>Mafi</surname><given-names>M</given-names></name></person-group>. <article-title>Effect of Leventhal&#x02019;s self-regulatory model on illness perception in women with gestational diabetes: a randomized controlled clinical trial</article-title>. <source>J Mazandaran Univ Med Sci</source>. (<year>2019</year>) <volume>29</volume>:<fpage>111</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Envelope</surname><given-names>S.</given-names></name></person-group>
<article-title>Create a blocked randomization list. Obtenido de sealed Envelope</article-title> (<year>2019</year>). Available online at: <ext-link xlink:href="https://www.sealedenvelope.com/simple" ext-link-type="uri">https://www.sealedenvelope.com/simple</ext-link> (Accessed January 12, 2020).</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Grimes</surname><given-names>DA</given-names></name></person-group>. <article-title>Generation of allocation sequences in randomized trials: chance, not choice</article-title>. <source>Lancet</source>. (<year>2002</year>) <volume>359</volume>:<fpage>515</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(02)07683-3</pub-id>, PMID: <pub-id pub-id-type="pmid">11853818</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klineova</surname><given-names>S</given-names></name><name><surname>Lublin</surname><given-names>FD</given-names></name></person-group>. <article-title>Clinical course of multiple sclerosis</article-title>. <source>Cold Spring Harb Perspect Med</source>. (<year>2018</year>) <volume>8</volume>:a028928. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a028928</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>TR</given-names></name><name><surname>Coote</surname><given-names>S</given-names></name><name><surname>Costello</surname><given-names>K</given-names></name><name><surname>Dalgas</surname><given-names>U</given-names></name><name><surname>Garmon</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course</article-title>. <source>Mult Scler J</source>. (<year>2020</year>) <volume>26</volume>:<fpage>1459</fpage>&#x02013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458520915629</pub-id>, PMID: <pub-id pub-id-type="pmid">32323606</pub-id>
</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagur</surname><given-names>MJ</given-names></name><name><surname>Murcia</surname><given-names>MA</given-names></name><name><surname>Jim&#x000e9;nez-Monreal</surname><given-names>AM</given-names></name><name><surname>Tur</surname><given-names>JA</given-names></name><name><surname>Bibiloni</surname><given-names>MM</given-names></name><name><surname>Alonso</surname><given-names>GL</given-names></name><etal/></person-group>. <article-title>Influence of diet in multiple sclerosis: a systematic review</article-title>. <source>Adv Nutr</source>. (<year>2017</year>) <volume>8</volume>:<fpage>463</fpage>&#x02013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.3945/an.116.014191</pub-id>, PMID: <pub-id pub-id-type="pmid">28507011</pub-id>
</mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri</surname><given-names>M</given-names></name><name><surname>Maghsoudi</surname><given-names>Z</given-names></name><name><surname>Fayazi</surname><given-names>S</given-names></name><name><surname>Elahi</surname><given-names>N</given-names></name><name><surname>Tabesh</surname><given-names>H</given-names></name><name><surname>Majdinasab</surname><given-names>N</given-names></name></person-group>. <article-title>Several food items and multiple sclerosis: a case&#x02013;control study in Ahvaz (Iran)</article-title>. <source>Iran J Nurs Midwifery Res</source>. (<year>2014</year>) <volume>19</volume>:<fpage>659</fpage>&#x02013;<lpage>65</lpage>. PMID: <pub-id pub-id-type="pmid">25558266</pub-id>
</mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekmezovic</surname><given-names>TD</given-names></name><name><surname>Tepavcevic</surname><given-names>DBK</given-names></name><name><surname>Mesaros</surname><given-names>ST</given-names></name><name><surname>Basuroski</surname><given-names>IBD</given-names></name><name><surname>Stojsavljevic</surname><given-names>NS</given-names></name><name><surname>Drulovic</surname><given-names>JS</given-names></name></person-group>. <article-title>Food and dietary patterns and multiple sclerosis: a case&#x02013;control study in Belgrade (Serbia)</article-title>. <source>Italian J Public Health</source>. (<year>2009</year>) <volume>6</volume>:81&#x02013;87. doi: <pub-id pub-id-type="doi">10.2427/5808</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccio</surname><given-names>P</given-names></name><name><surname>Rossano</surname><given-names>R</given-names></name></person-group>. <article-title>Nutrition facts in multiple sclerosis</article-title>. <source>ASN Neuro</source>. (<year>2015</year>) <volume>7</volume>:<fpage>1759091414568185</fpage>. doi: <pub-id pub-id-type="doi">10.1177/1759091414568185</pub-id>, PMID: <pub-id pub-id-type="pmid">25694551</pub-id>
</mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Schmitz</surname><given-names>F</given-names></name></person-group>. <article-title>Synapse dysfunctions in multiple sclerosis</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<fpage>1639</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24021639</pub-id>, PMID: <pub-id pub-id-type="pmid">36675155</pub-id>
</mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name></person-group>. <article-title>Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis</article-title>. <source>Nat Rev Neurol</source>. (<year>2017</year>) <volume>13</volume>:<fpage>25</fpage>&#x02013;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrneurol.2016.187</pub-id>, PMID: <pub-id pub-id-type="pmid">27934854</pub-id>
</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farez</surname><given-names>MF</given-names></name><name><surname>Fiol</surname><given-names>MP</given-names></name><name><surname>Gait&#x000e1;n</surname><given-names>MI</given-names></name><name><surname>Quintana</surname><given-names>FJ</given-names></name><name><surname>Correale</surname><given-names>J</given-names></name></person-group>. <article-title>Sodium intake is associated with increased disease activity in multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>2015</year>) <volume>86</volume>:<fpage>26</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2014-307928</pub-id>, PMID: <pub-id pub-id-type="pmid">25168393</pub-id>
</mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashynka</surname><given-names>A</given-names></name><name><surname>Leone</surname><given-names>MA</given-names></name><name><surname>Barizzone</surname><given-names>N</given-names></name><name><surname>Cucovici</surname><given-names>A</given-names></name><name><surname>Cantello</surname><given-names>R</given-names></name><name><surname>Vecchio</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The impact of lifetime coffee and tea loads on multiple sclerosis severity</article-title>. <source>Clinical Nutrition ESPEN</source>. (<year>2022</year>) <volume>47</volume>:<fpage>199</fpage>&#x02013;<lpage>205</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clnesp.2021.12.014</pub-id>, PMID: <pub-id pub-id-type="pmid">35063202</pub-id>
</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>P</given-names></name><name><surname>Rafatnia</surname><given-names>F</given-names></name><name><surname>B&#x000e4;&#x000e4;rnhielm</surname><given-names>M</given-names></name><name><surname>Fr&#x000f6;bom</surname><given-names>R</given-names></name><name><surname>Korzunowicz</surname><given-names>G</given-names></name><name><surname>L&#x000f6;nnerbro</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Neonatal vitamin D status and risk of multiple sclerosis</article-title>. <source>Ann Neurol</source>. (<year>2014</year>) <volume>76</volume>:<fpage>338</fpage>&#x02013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.24210</pub-id>, PMID: <pub-id pub-id-type="pmid">24985080</pub-id>
</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotstein</surname><given-names>DL</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Fung</surname><given-names>TT</given-names></name><name><surname>Chitnis</surname><given-names>T</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name></person-group>. <article-title>Diet quality and risk of multiple sclerosis in two cohorts of US women</article-title>. <source>Mult Scler J</source>. (<year>2019</year>) <volume>25</volume>:<fpage>1773</fpage>&#x02013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458518807061</pub-id>, PMID: <pub-id pub-id-type="pmid">30351179</pub-id>
</mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>BM</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name></person-group>. <article-title>Systematic review and meta-analysis of the association between Epstein&#x02013;Barr virus, multiple sclerosis and other risk factors</article-title>. <source>Mult Scler J</source>. (<year>2020</year>) <volume>26</volume>:<fpage>1281</fpage>&#x02013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458520907901</pub-id>, PMID: <pub-id pub-id-type="pmid">32202208</pub-id>
</mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Lima Bomfim</surname><given-names>I</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name></person-group>. <article-title>Obesity interacts with infectious mononucleosis in risk of multiple sclerosis</article-title>. <source>Eur J Neurol</source>. (<year>2015</year>) <volume>22</volume>:<fpage>578</fpage>&#x02013;<lpage>e38</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.12620</pub-id>, PMID: <pub-id pub-id-type="pmid">25530445</pub-id>
</mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghazaiean</surname><given-names>M</given-names></name><name><surname>Darvishi-Khezri</surname><given-names>H</given-names></name><name><surname>Baghbanian</surname><given-names>SM</given-names></name></person-group>. <article-title>Relationship between medical history and multiple sclerosis: a-case&#x02013;control study</article-title>. <source>Medicine</source>. (<year>2023</year>) <volume>102</volume>:<fpage>e33906</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000033906</pub-id>, PMID: <pub-id pub-id-type="pmid">37335649</pub-id>
</mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Larsson</surname><given-names>SC</given-names></name></person-group>. <article-title>An atlas on risk factors for multiple sclerosis: a Mendelian randomization study</article-title>. <source>J Neurol</source>. (<year>2021</year>) <volume>268</volume>:<fpage>114</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-020-10119-8</pub-id>, PMID: <pub-id pub-id-type="pmid">32728946</pub-id>
</mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarlinton</surname><given-names>RE</given-names></name><name><surname>Martynova</surname><given-names>E</given-names></name><name><surname>Rizvanov</surname><given-names>AA</given-names></name><name><surname>Khaiboullina</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name></person-group>. <article-title>Role of viruses in the pathogenesis of multiple sclerosis</article-title>. <source>Viruses</source>. (<year>2020</year>) <volume>12</volume>:<fpage>643</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v12060643</pub-id>, PMID: <pub-id pub-id-type="pmid">32545816</pub-id>
</mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname><given-names>A</given-names></name><name><surname>Riefflin</surname><given-names>M</given-names></name><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Riemann-Lorenz</surname><given-names>K</given-names></name><name><surname>Obi</surname><given-names>N</given-names></name><name><surname>Becher</surname><given-names>H</given-names></name></person-group>. <article-title>Breastfeeding and risk of multiple sclerosis: a systematic review and meta-analysis of observational studies</article-title>. <source>Neuroepidemiology</source>. (<year>2023</year>) <volume>56</volume>:<fpage>391</fpage>&#x02013;<lpage>401</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000526895</pub-id>, PMID: <pub-id pub-id-type="pmid">36096115</pub-id>
</mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gascoyne</surname><given-names>CR</given-names></name><name><surname>Simpson</surname><given-names>S</given-names><suffix>Jr</suffix></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>van der Mei</surname><given-names>I</given-names></name><name><surname>Marck</surname><given-names>CH</given-names></name></person-group>. <article-title>Modifiable factors associated with depression and anxiety in multiple sclerosis</article-title>. <source>Acta Neurol Scand</source>. (<year>2019</year>) <volume>140</volume>:<fpage>204</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ane.13132</pub-id>, PMID: <pub-id pub-id-type="pmid">31121055</pub-id>
</mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaraghchi</surname><given-names>A</given-names></name><name><surname>Rezaei</surname><given-names>O</given-names></name><name><surname>Mandegar</surname><given-names>MH</given-names></name><name><surname>Bagherian</surname><given-names>R</given-names></name></person-group>. <article-title>The relationship between illness perception and quality of life in Iranian patients with coronary artery bypass graft</article-title>. <source>Procedia Soc Behav Sci</source>. (<year>2012</year>) <volume>46</volume>:<fpage>3329</fpage>&#x02013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.sbspro.2012.06.061</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovibond</surname><given-names>PF</given-names></name><name><surname>Lovibond</surname><given-names>SH</given-names></name></person-group>. <article-title>The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories</article-title>. <source>Behav Res Ther</source>. (<year>1995</year>) <volume>33</volume>:<fpage>335</fpage>&#x02013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0005-7967(94)00075-U</pub-id>, PMID: <pub-id pub-id-type="pmid">7726811</pub-id>
</mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sahebi</surname><given-names>A</given-names></name><name><surname>Asghari</surname><given-names>MJ</given-names></name><name><surname>Salari</surname><given-names>RS</given-names></name></person-group>. <source>Validation of depression anxiety and stress scale (DASS-21) for an Iranian population</source>. (<year>2005</year>).</mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zer</surname><given-names>D</given-names></name><name><surname>Ata</surname><given-names>EE</given-names></name><name><surname>Dike&#x000e7;</surname><given-names>G</given-names></name><name><surname>Demir</surname><given-names>S</given-names></name></person-group>. <article-title>The relationship between stress, anxiety, and depression levels and pseudobulbar affect in patients with multiple sclerosis</article-title>. <source>Contemp Nurse</source>. (<year>2022</year>) <volume>58</volume>:<fpage>317</fpage>&#x02013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1080/10376178.2022.2107037</pub-id>, PMID: <pub-id pub-id-type="pmid">35880717</pub-id>
</mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Peral</surname><given-names>P</given-names></name><name><surname>Conejo-Ceron</surname><given-names>S</given-names></name><name><surname>Rubio-Valera</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>A</given-names></name><name><surname>Navas-Campana</surname><given-names>D</given-names></name><name><surname>Rodriguez-Morejon</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Effectiveness of psychological and/or educational interventions in the prevention of anxiety: a systematic review, meta-analysis, and meta-regression</article-title>. <source>JAMA Psychiatry</source> (<year>2017</year>);<volume>74</volume>:<fpage>1021</fpage>&#x02013;<lpage>1029</lpage>, doi: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.2509</pub-id>, PMID: , PMCID: <!--<pub-id pub-id-type="pmcid">PMC5710546</pub-id>-->.<pub-id pub-id-type="pmid">28877316</pub-id>
</mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeling</surname><given-names>M</given-names></name><name><surname>Bambrough</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>J</given-names></name></person-group>. <article-title>Depression, anxiety and positive affect in people diagnosed with low-grade tumors: the role of illness perceptions</article-title>. <source>Psychooncology</source>. (<year>2013</year>) <volume>22</volume>:<fpage>1421</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pon.3158</pub-id>, PMID: <pub-id pub-id-type="pmid">22991130</pub-id>
</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowicka-Sauer</surname><given-names>K</given-names></name><name><surname>Hajduk</surname><given-names>A</given-names></name><name><surname>Kujawska-Danecka</surname><given-names>H</given-names></name><name><surname>Banaszkiewicz</surname><given-names>D</given-names></name><name><surname>Smole&#x00144;ska</surname><given-names>&#x0017b;</given-names></name><name><surname>Czuszy&#x00144;ska</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Illness perception is significantly determined by depression and anxiety in systemic lupus erythematosus</article-title>. <source>Lupus</source>. (<year>2018</year>) <volume>27</volume>:<fpage>454</fpage>&#x02013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0961203317751858</pub-id>, PMID: <pub-id pub-id-type="pmid">29325492</pub-id>
</mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>D</given-names></name><name><surname>Simamohammadkhan</surname><given-names>K</given-names></name><name><surname>Robabeh</surname><given-names>M</given-names></name></person-group>. <article-title>The effect of peer group educational program on multiple sclerosis patient's level of stress</article-title>. <source>J Arak University Med Sci</source>. (<year>2012</year>) <volume>15</volume>:<fpage>17</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shnek</surname><given-names>ZM</given-names></name><name><surname>Foley</surname><given-names>FW</given-names></name><name><surname>LaRocca</surname><given-names>NG</given-names></name><name><surname>Smith</surname><given-names>CR</given-names></name><name><surname>Halper</surname><given-names>J</given-names></name></person-group>. <article-title>Psychological predictors of depression in multiple sclerosis</article-title>. <source>J Neurol Rehab</source>. (<year>1995</year>) <volume>9</volume>:<fpage>15</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1177/154596839500900103</pub-id>, PMID: <pub-id pub-id-type="pmid">40270978</pub-id>
</mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sararoudi</surname><given-names>RB</given-names></name><name><surname>Motmaen</surname><given-names>M</given-names></name><name><surname>Maracy</surname><given-names>MR</given-names></name><name><surname>Pishghadam</surname><given-names>E</given-names></name><name><surname>Kheirabadi</surname><given-names>GR</given-names></name></person-group>. <article-title>Efficacy of illness perception focused intervention on quality of life, anxiety, and depression in patients with myocardial infarction</article-title>. <source>J Res Med Sci</source>. (<year>2016</year>) <volume>21</volume>:<fpage>125</fpage>. doi: <pub-id pub-id-type="doi">10.4103/1735-1995.196607</pub-id>, PMID: <pub-id pub-id-type="pmid">28331511</pub-id>
</mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Villiers-Tuthill</surname><given-names>A</given-names></name><name><surname>Barker</surname><given-names>M</given-names></name><name><surname>McGee</surname><given-names>H</given-names></name></person-group>. <article-title>The contribution of illness perception to psychological distress in heart failure patients</article-title>. <source>BMC Psychol</source>. (<year>2014</year>) <volume>2</volume>:<fpage>50</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40359-014-0050-3</pub-id><pub-id pub-id-type="pmid">25520809</pub-id>
</mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Florez</surname><given-names>KB</given-names></name><name><surname>S&#x000e1;nchez-Castillo</surname><given-names>H</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>P</given-names></name><name><surname>Zarate</surname><given-names>P</given-names></name><name><surname>Paz</surname><given-names>DB</given-names></name></person-group>. <article-title>Stress, a brief update</article-title>. <source>Int J Psychol Res</source>. (<year>2023</year>) <volume>16</volume>:<fpage>105</fpage>&#x02013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.21500/20112084.5815</pub-id>, PMID: <pub-id pub-id-type="pmid">38106958</pub-id>
</mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavroeides</surname><given-names>G</given-names></name><name><surname>Koutra</surname><given-names>K</given-names></name></person-group>. <article-title>Illness representations in depression and their association with clinical and treatment outcomes: a systematic review of the literature</article-title>. <source>J Affective Disorders Reports</source>. (<year>2021</year>) <volume>4</volume>:<fpage>100099</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jadr.2021.100099</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkan-Sat</surname><given-names>S</given-names></name><name><surname>Is&#x00131;k</surname><given-names>M</given-names></name></person-group>. <article-title>The effect of psychoeducation based on Leventhal's self-regulation model on Dysmenorrhoea in nursing students: a single-blind randomized controlled study</article-title>. <source>Pain Manag Nurs</source>. (<year>2024</year>) <volume>25</volume>:<fpage>e311</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pmn.2024.03.003</pub-id>, PMID: <pub-id pub-id-type="pmid">38555264</pub-id>
</mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saranjam</surname><given-names>F</given-names></name><name><surname>Afrasiabifar</surname><given-names>A</given-names></name><name><surname>Alamdari</surname><given-names>A</given-names></name><name><surname>Hosseini</surname><given-names>N</given-names></name></person-group>. <article-title>Effect of Leventhal&#x02019;s self-regulatory intervention on the hypertensive patients&#x02019; illness perception and lifestyle: a randomized controlled trial</article-title>. <source>BMC Cardiovasc Disord</source>. (<year>2023</year>) <volume>23</volume>:<fpage>50</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12872-023-03049-6</pub-id>, PMID: <pub-id pub-id-type="pmid">36703112</pub-id>
</mixed-citation></ref></ref-list></back></article>